Recent Updates
Recently added Catalysts
SNWV Positive Sentiment

Sanuwave Will Host a Conference Call on November 11, 2026 at 8:30 AM (ET) to Present Q3 2026 Financial Results

Key Takeaway: Sanuwave Health, Inc. will host a conference call on November 11, 2026, at 8:30 AM (ET) to discuss its Q3 2026 financial results. The call will be accessible via telephone and a live webcast. Materials related to the call will be available on the company's investor website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Sanuwave will present Q3 2026 financial results.
  • The company continues to develop FDA-approved wound care products.
  • A live conference call will provide direct access to financial updates.

Full Press Release Details

EDEN PRAIRIE, Minn., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Wednesday, November 11, 2026, at 8:30 AM (ET) to present its Q3 2026 financial results.
Telephone access to the call will be available by dialing the following numbers:

Participant Dial-in Information

Toll Free: 1-800-420-1459

Toll/International: 1-203-518-9861

Conference ID: SANUWAVE

OR click the link below to access the live webcast: https://viavid.webcasts.com/starthere.jsp?ei=1777177&tp_key=6fc0abed5c
Materials for the conference call will be included on the Company’s website at www.sanuwave.com/investors.
A replay will be made available through Wednesday, November 25, 2026:
Toll-Free: 1-844-512-2921
Toll/International: 1-412-317-6671
Replay Access ID: 11162619

About Sanuwave

Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

Frequently Asked Questions

When is Sanuwave's conference call for Q3 2026?

The conference call is scheduled for November 11, 2026, at 8:30 AM (ET).

How can I access the Sanuwave conference call?

You can access it by dialing 1-800-420-1459 or via the provided webcast link.

Will there be a replay of the conference call?

Yes, a replay will be available until November 25, 2026.

What topics will Sanuwave cover in the call?

The call will cover the company's Q3 2026 financial results.

Last updated: Nov 6, 2026